[1]中国基本医保覆盖13.5亿人住院费用报销超60%[EB/OL].(2020-06-27)[2021-09-20]. http://www.gov.cn/xinwen/2020-06/27/content_5522166.htm.
[2]Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study[J]. 2020, 369: m997.
[3]Mcguire HC, Ji L, Kissimova-Skarbek K, et al. Type 1 diabetes mellitus care and education in China: The 3C study of coverage, cost, and care in Beijing and Shantou[J]. Diabetes Res Clin Pract, 2017, 129: 32-42.
[4]中华医学会糖尿病分会. 中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志, 2018, 10(1): 4-67.
[5]Peters, AL. The Evidence Base for Continuous Glucose Monitoring[J]. Role of Continuous Glucose Monitoring in Diabetes Treatment, 2018: 3-7.
[6]Melanie A, Ahmann A, Shah VN. Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring[J]. Diabetes Technol Ther, 2021, 23(S1): S27-S34.
[7]American Diabetes Association. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2020[J]. Diabetes Care, 2020, 43(Suppl 1): S37-S47.
[8]Bolinder J, Antuna R, Geelhoed-Duijvestijn, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial[J]. Lancet, 2016, 388(10057): 2254-2263.
[9]Haak T, Hanaire H, Ajjan R, et al. Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial[J]. Diabetes Ther, 2017, 8(1): 55-73.
[10]Lan K, Wang J, Nicholas S, et al. Is hypoglycemia expensive in China [J]. Medicine (Baltimore), 2021, 100(5): e24067.
[11]Yaron M, Roitman E, Aharon-Hananel G, et al. Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes[J]. Diabetes Care, 2019, 42(7): 1178-1184.
[12]Roussel R, Guerci B, Vicaut E, et al. Dramatic drop in ketoacidosis rate after freestyle libre system initiation in type 1 and type 2 diabetes in france, especially in people with low self-monitoring of blood glucose (SMBG): A Nationwide Study[C].Proceedings of 80th American Diabetes Association Scientific Sessions. Virtual. 2020. Virginia: American Diabetes Association, 2020.
[13]Wu H, Eggleston KN, Zhong J, et al. How do type 2 diabetes mellitus (T2DM)-related complications and socioeconomic factors impact direct medical costs? A cross-sectional study in rural Southeast China[J]. BMJ Open, 2018, 8(11):e020647.
[14]Wehler E, Li H, Bilir P, et al. Cost effectiveness analysis of a flash continuous glucose monitoring system for type 2 diabetes (T2DM) patients receiving intensive insulin treatment in the UK[R]. Value in health, PMD60.
[15]Huang ES, O′Grady M, Basu A, et al. The cost-effectiveness of continuous glucose monitoring in type 1 diabetes[J]. Diabetes Care, 2010, 33(6): 1269-1274.
[16]国家卫生健康委员. 中国卫生健康统计年鉴[R]. 中国协和医科大学出版社, 2020.
[17]刘国恩. 中国药物经济学评价指南[M].北京: 中国市场出版社, 2020: 92-93.
[18]南都健康联盟. 健康中国2020健康体检白皮书糖尿病防控报告[R]. 2020.
[19]Yue X, Wu J, Ruan Z, et al. The Burden of Hypoglycemia in Patients With Insulin-Treated Diabetes Mellitus in China: Analysis of Electronic Medical Records From 4 Tertiary Hospitals[J]. Value in Health Regional Issues, 2020, 21(C): 17-21.
[20]屈丹, 刑桂红, 徐宏旦, 等. 门诊2 型糖尿病患者低血糖现况调查[J]. 中国慢性病预防与控制, 2015, 23(8): 602-604.
[21]Duan X, Li Y, Liu Q, et al. Epidemiological characteristics, medical costs and healthcare resource utilization of diabetes-related complications among Chinese patients with type 2 diabetes mellitus[J]. Expert Rev Pharmacoecon Outcomes Res, 2020, 20(5): 513-521.
[22]王旭颖. 2 型糖尿病患者生活方式调查及就诊费用分析[D]. 天津, 2018.
[23]Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range[J]. Diabetes Care, 2019, 42(8): 1593-1603.
[24]邓明群, 周丽媛, 翟笑, 等. 扫描式葡萄糖监测系统中目标范围时间与糖化血红蛋白的相关性[J]. 协和医学杂志, 2021, 12(4): 526-530.
[25]中华医学会糖尿病分会. 中国持续葡萄糖监测临床应用指南(2017年版)[J]. 中华糖尿病杂志, 2017, 9(11): 667-675.
[26]姚静静, 王海鹏, 孙强. 山东省2型糖尿病患者自付医疗费用和疾病经济风险现状分析[J]. 中国卫生政策研究, 2019, 12(7): 75-80.
[27]Foos V, Wang K, McEwan P, et al. Assessing the Burden of Type 2 Diabetes in China Considering the Current Status-Quo Management and Implications of Improved Management Using a Modeling Approach[J]. Value Health Reg Issues, 2019, 18: 36-46. |